Fully automatic aseptic liquid filling system - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fully automatic aseptic liquid filling system


The FPC50W is a flexible aseptic filling system with integrated full or partial stoppering and crimp capping of vials. The system can deliver fill volumes ranging from 0.1ml to 100ml and a filling accuracy of ± 0.5% which is check-weighed throughout the filling batch, with adjustments made automatically if required.

The FPC50W is ideally suited to applications involving small batches such as contract fillers and research and development trials where cross contamination must be avoided. For example, the use of Flexicon's asepticsu sterile, disposable tubing, filling needles and fluid bags, ensures minimal human contact with the filling operation. In addition, the entire single-use fluid path is contained, making cleaning and validation extremely simple.

As well as check-weighing 100% of the vials filled, the FPC50W also permits fast change-over between batches of liquids to be filled. This helps to eliminate time consuming and costly logistic procedures related to having dedicated pumps in stock.

Peristaltic pumps are ideally suited to filling applications: they provide superior flow rate stability and metering accuracy; facilitate aseptic and sterile processes; have extensive chemical compatibility; and are inherently hygienic and safe to run.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here